Combination polypharmacy for cardiovascular disease prevention in men: A decision analysis and cost-effectiveness model

Preventive Cardiology

Volumn 11, Issue 1, 2008, Pages 36-41

  Newman, Jonathan ^a,b   Grobman, William A ^b   Greenland, Philip ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CAPTOPRIL; HYDROCHLOROTHIAZIDE; SIMVASTATIN; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; COLD LIMB; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COUGHING; DIZZINESS; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; HUMAN; HYPERTENSION; IMPOTENCE; MALE; MORTALITY; MUSCLE CRAMP; MYOPATHY; NAUSEA; POLYPHARMACY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHABDOMYOLYSIS; SENSITIVITY ANALYSIS; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COMBINATION; ECONOMICS; MIDDLE AGED; PROBABILITY;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MARKOV CHAINS; MIDDLE AGED;

EID: 41149083459     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1520-037X.2007.06423.x     Document Type: Article

References (48)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, TX: American Heart Association; 2005.
2. Bonow RO, Smaha LA, Smith SC Jr, et al. World Heart Day 2002: The international burden of cardiovascular disease: Responding to the emerging global epidemic. Circulation. 2002;106:1602-1605.
3. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004;291:2847-2850.
4. Centers for Disease Control and Prevention. Adult participation in recommended levels of physical activity-United States, 2001 and 2003. MMWR Morb Mortal Wkly Rep. 2005;54(47):1208-1212.
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCaps. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
6. Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling Project. Eur Heart J. 2002;23:207-215.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
8. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo controlled trial. Lancet. 2002;360(9326):7-22.
9. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressuring lowering drugs: Results of prospectively designed overviews of randomized trials. Lancet. 2000;356(9246):1955-1964.
10. Wong ND, Thakral G, Franklin SS, et al. Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex. Am Heart J. 2003;145:888-895.
11. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomized controlled trials. Lancet. 2003;362(9395):1527-1535.
12. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
13. Combination Pharmacotherapy and Public Health Research Working Group. Combination pharmacotherapy for cardiovascular disease. Ann Intern Med. 2005;143:593-599.
14. National Vital Statistics Reports. United States Life Tables, 2002. Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention; 2002.
15. Hurst W. The Heart, Arteries and Veins. 11th ed. New York, NY: McGraw-Hill; 2004.
16. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987-1994. N Engl J Med. 1998;339:861-867.
17. Peeters A, Mamum AA, Willekens F, et al. A cardiovascular life history: a life course analysis of the original Framingham heart study cohort. Eur Heart J. 2002;23:458-466.
18. Brown RD, Whisnant JP, Sicks JD, et al. Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373-380.
19. Derby CA, Lapane KL, Feldman HA, et al. Trends in validated cases of fatal and nonfatal stroke, stroke classification, and risk factors in southeastern New England, 1980-1991: Data from the Pawtucket Heart Health Program. Stroke. 2000;31:875-881.
20. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415-421.
21. Williams GR, Jiang, JG, Matchar DB, et al. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke. 1999;20:2523-2528.
22. Ayala C, Croft JB, Greenlund KJ, et al. Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age. Stroke. 2002;33:1197-1201.
23. Ayala C, Greelund KJ, Croft JB, et al. Racial/ethnic disparities in mortality by stroke subtype in the US 1995-1998. Am J Epidemiology. 2001;154;1057-1063.
24. Hannerz H, Nielsen ML. Life expectancies among survivors of acute cerebrovascular disease. Stroke. 2001;32:1739-1744.
25. Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
26. Pignone M, Earnshaw S, Tice J. Aspirin, statins or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Ann Intern Med. 2006;144:326-336.
27. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152-160.
28. Law MR, Wald NJ. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ. 2003;326:1427-1434.
29. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637-1642.
30. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62(15):28J-34J.
31. Graham DJ, Staffa JA. Incidence of hospitalized rhabdomyolysis in patients treated with lipid lowering drugs. JAMA. 2004;292:2585-2590.
32. Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med. 1988;148:1553-1557.
33. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539-540.
34. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-1427.
35. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-372.
36. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1998;128:89-95.
37. Amerenco P, Labreuche J. Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta analysis. Stroke. 2004;35:2902-2909.
38. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996;156:1969-1978.
39. Chrysant SG, Fagan T, Glazer R, et al. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 1996;5:17-24.
40. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med. 1994;154:1461-1468.
41. Lewington S, Clarke R, Qizilbash N, et al; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913.
42. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335(8693):827-838.
43. Nyman JA, Martinson MS, Nelson D, et al. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: The Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. Arch Intern Med. 2002;162:177-182.
44. Fleming T. 2004 Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Medical Economics Data; 2004.
45. http://www.drugstore.com/pharmacy/drugindex/rxsearch.asp?search= simvastin, atenolol, HCTZ, lisinopril. Accessed December 2005.
46. Gotto AM Jr, Boccuzzi SJ, Cook JR, et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/ TexCAPS Research Group. Am J Cardiol. 2000;86:1176-1181.
47. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161-165.
48. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.